State-of-the-art procedures and quality management in diagnostic medical mycology

Current Fungal Infection Reports

Volumn 7, Issue 3, 2013, Pages 260-272

  Willinger, Birgit ^a   Haase, Gerhard ^b  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

Author keywords

Antifungal susceptibility testing; Culture; Diagnosis; Histology; Identification; MALDI TOF; Microscopy; Molecular techniques; Moulds; PCR; Quality management; Sequence analysis; Yeast

Indexed keywords

CANDIDA ANTIGEN; GALACTOMANNAN; GLUCAN; POTASSIUM HYDROXIDE;

ANTIBODY DETECTION; ANTIBODY SCREENING; ANTIFUNGAL SUSCEPTIBILITY; ANTIMICROBIAL THERAPY; ARTICLE; ASPERGILLUS; BIOPSY; BLOOD CULTURE; BLOODSTREAM INFECTION; BONE DENSITOMETRY; CANDIDA ALBICANS; CANDIDA FAMATA; CANDIDA GLABRATA; CAPNOCYTOPHAGA; CELL STRUCTURE; CEREBROSPINAL FLUID CULTURE; CRYPTOCOCCOSIS; CRYPTOCOCCUS; CRYPTOCOCCUS NEOFORMANS; DIAGNOSTIC PROCEDURE; DIAGNOSTIC VALUE; DISSEMINATED TRICHOSPORONOSIS; DNA EXTRACTION; DNA PURIFICATION; ENZYME ISOLATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FALSE NEGATIVE RESULT; FALSE POSITIVE RESULT; FATALITY; FUNGAL CELL; FUNGAL CELL WALL; FUNGUS CULTURE; FUNGUS IDENTIFICATION; HEALTH CARE QUALITY; HISTOLOGY; HISTOPATHOLOGY; IMMUNOASSAY; INVASIVE ASPERGILLOSIS; INVASIVE CANDIDIASIS; LABORATORY DIAGNOSIS; LATEX AGGLUTINATION TEST; LIQUID; LOOP MEDIATED ISOTHERMAL AMPLIFICATION; LUNG LAVAGE; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MICROSCOPY; MINIMUM INHIBITORY CONCENTRATION; MUCORMYCOSIS; MULTIPLEX POLYMERASE CHAIN REACTION; MYCOLOGY; NONHUMAN; NUCLEIC ACID AMPLIFICATION; QUALITY CONTROL; RANDOM AMPLIFIED POLYMORPHIC DNA; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SENSITIVITY AND SPECIFICITY; SEPTICEMIA; SYSTEMIC MYCOSIS; TOTAL QUALITY MANAGEMENT;

EID: 84883454767     PISSN: 19363761     EISSN: 1936377X     Source Type: Journal    
DOI: 10.1007/s12281-013-0145-y     Document Type: Article

References (98)

1. Lehrnbecher T, Frank C, et al. Trends in the postmortem epidemiology of invasive fungal infections at a university hospital. J Infect. 2010;61(3):259-65.
2. Martin GS. Sepsis, severe sepsis and septic shock: changes in incidence, pathogens and outcomes. Expert Rev Anti Infect Ther. 2012;10(6):701-6.
3. Brown GD, Denning DW, et al. Tackling human fungal infections. Science. 2012;336:647.
4. Bartlett RC, Mazens-Sullivan M, et al. Evolving approaches to management of quality in clinical microbiology. Clin Microbiol Rev. 1994;7:55-88.
5. •• Clinical and Laboratory Standards (CLSI). Principles and Procedures for Detection of Fungi in Clinical Specimens - Direct Examination and Culture; Approved Guideline. CLSI document M54-A. Clinical and Laboratory Standards Institute, 950 West Valley Road, Suite 2500, Wayne, Pennsylvania 19087 USA, 2012. This document addresses the principles and procedures for the detection of fungi in clinical specimens, including QC processes unique to the mycology laboratory.
6. •• Vyzantiadis TA, Johnson EM, et al. From the patient to the clinical mycology laboratory: how can we optimise microscopy and culture methods for mould identification? J Clin Pathol. 2012;65(6):475-83. This review summarises and evaluates the evidence for the major existing phenotypic identification procedures for the predominant causes of opportunistic mould infection.
7. •• Arendrup MC, Bille J, et al. ECIL-3 classical diagnostic procedures for the diagnosis of invasive fungal diseases in patients with leukaemia. Bone Marrow Transplant. 2012;47(8):1030-45. The working group of the European Conference in Infections in Leukaemia reviewed the classical diagnostic procedures and provide recommendations for their optimal use.
8. Denning DW, Kibbler CC, et al. British society for medical mycology proposed standards of care for patients with invasive fungal infections. Lancet Infect Dis. 2003;3(4):230-40.
9. Ribes JA, Vanover-Sams CL, et al. Zygomycetes in human disease. Clin Microbiol Rev. 2000;13(2):236-301.
10. Meersseman W, Lagrou K, et al. Significance of the isolation of Candida species from airway samples in critically ill patients: a prospective, autopsy study. Intensive Care Med. 2009;35(9):1526-31.
11. Alexander BD. Diagnosis of fungal infection: new technologies for the mycology laboratory. Transpl Infect Dis. 2002;4 Suppl 3:32-7.
12. De Pauw B, Walsh TJ, et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis. 2008;46(12):1813-21.
13. • Chandrasekar P. Diagnostic challenges and recent advances in the early management of invasive fungal infections. Eur J Haematol. 2010;84(4):281-90. This article reviews current approaches to diagnosis and treatment.
14. Alexander B, Pfaller M. Contemporary tools for the diagnosis and management of invasive mycoses. Clin Infect Dis. 2006;43 Suppl 1:S15-27.
15. •• Lease ED, Alexander BD. Fungal diagnostics in pneumonia. Semin Respir Crit Care Med. 2011;32(6):663-72. This article reviews the laboratory tools used to diagnose fungal respiratory disease.
16. Willinger B. Laboratory diagnosis and therapy of invasive fungal infections. Curr Drug Targets. 2006;7(4):513-22.
17. Arendrup MC, Chryssanthou E, Gaustad P, Koskela M, Sandven P, Fernandez V. Diagnostics of fungal infections in the Nordic countries: we still need to improve! Scand J Infect Dis. 2007;39(4):337-43.
18. Freydiere AM, Guinet R, Boiron P. Yeast identification in the clinical microbiology laboratory: phenotypical methods. Med Mycol. 2001;39(1):9-33.
19. de Hoog GS, Haase G. Nutritional physiology and selective isolation of Exophiala dermatitidis. Antonie Van Leeuwenhoek. 1993;64(1):17-26.
20. Blyth CC, Harun A, et al. Detection of occult Scedosporium species in respiratory tract specimens from patients with cystic fibrosis by use of selective media. J Clin Microbiol. 2010;48(1):314-6.
21. • Lackner M, Lass-Floerl C. Up-date on diagnostic strategies of invasive Aspergillosis. Curr Pharm Des. 2012; epub ahead print. This paper reviews diagnostic aspects of invasive aspergillosis.
22. Ostrosky-Zeichner L. Invasive mycoses: diagnostic challenges. Am J Med. 2012;125(1 Suppl):S14-24.
23. •• Cuenca-Estrella M, Verweij PE, et al. ESCMID*guideline for the diagnosis and management of Candida diseases 2012: diagnostic procedures. Clin Microbiol Infect. 2012;18 Suppl 7:9-18. The authors compiled guidelines for the clinical utility and accuracy of different diagnostic tests and procedures for detection of Candida infections.
24. Rimek D, Haase G, et al. First report of a case of meningitis caused by Cryptococcus adeliensis in a patient with acute myeloid leukemia. J Clin Microbiol. 2004;42(1):481-3.
25. Duthie R, Denning DW. Aspergillus fungemia: report of two cases and review. Clin Infect Dis. 1995;20(3):598-605.
26. Willinger B, Kienzl D et al. Diagnostics in Fungal Infections. In: Human Fungal Pathogens. Ed.: Kurzai O. 2013; in press
27. Müller FM, Trusen A, et al. Clinical manifestations and diagnosis of invasive aspergillosis in immunocompromised children. Eur J Pediatr. 2002;161(11):563-74.
28. de Hoog, S., J. Guarro, et al. Atlas of Clinical Fungi 2009; Electronic version 3.1, ASM Press.
29. Stevenson LG, Drake SK, et al. Evaluation of matrix-assisted laser desorption ionization-time of flight mass spectrometry for identification of clinically important yeast species. J Clin Microbiol. 2010;48(10):3482-6.
30. Croxatto A, Prod'hom G, et al. Applications of MALDI-TOF mass spectrometry in clinical diagnostic microbiology. FEMS Microbiol Rev. 2012;36(2):380-407.
31. •• Bader O. MALDI-TOF-MS-based species identification and typing approaches in medical mycology. Proteomics. 2013;13(5):788-99. This papers gives an overwiew of this technique in the field of medical mycology.
32. Marklein G, Josten M, et al. Matrix-assisted laser desorption ionization-time of flight mass spectrometry for fast and reliable identification of clinical yeast isolates. J Clin Microbiol. 2009;47(9):2912-7.
33. Lacroix C, Gicquel A, et al. Evaluation of two matrix-assisted laser desorption ionization-time of flight mass spectrometry (MALDI-TOF MS) systems for the identification of Candida species. Clin Microbiol Infect. 2013 Mar 7. [Epub ahead of print]
34. Jensen RH, Arendrup MC. Candida palmioleophila: characterization of a previously overlooked pathogen and its unique susceptibility profile in comparison with five related species. J Clin Microbiol. 2011;49(2):549-56.
35. Spanu T, Posteraro B, et al. Direct maldi-tof mass spectrometry assay of blood culture broths for rapid identification of Candida species causing bloodstream infections: an observational study in two large microbiology laboratories. J Clin Microbiol. 2012;50(1):176-9.
36. • Wieser A, Schneider L, et al. MALDI-TOF MS in microbiological diagnostics-identification of microorganisms and beyond (mini review). Appl Microbiol Biotechnol. 2012;93(3):965-74. This mini review provides an overview of the literature in the field and also includes the author's own data and experiences gathered from over 4 years of routine MALDI-TOF MS use.
37. de Respinis S, Tonolla M, et al. Identification of dermatophytes by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. Med Mycol 2012; [Epub ahead of print]
38. Nenoff P, Erhard M, et al. MALDI-TOF mass spectrometry - a rapid method for the identification of dermatophyte species. Med Mycol. 2013;51(1):17-24.
39. Dong H, Kemptner J, et al. Development of a MALDI two-layer volume sample preparation technique for analysis of colored conidia spores of Fusarium by MALDI linear TOF mass spectrometry. Anal Bioanal Chem. 2009;395(5):1373-83.
40. Buskirk AD, Hettick JM, et al. Fungal pigments inhibit the matrix-assisted laser desorption/ionization time-of-flight mass spectrometry analysis of darkly pigmented fungi. Anal Biochem. 2011;411(1):122-8.
41. • Jenkins SG, Schuetz AN. Current concepts in laboratory testing to guide antimicrobial therapy. Mayo Clin Proc. 2012;87(3):290-308. This paper gives a very clear and practical overview of antifungal susceptibility testing.
42. Pfaller MA. Antifungal drug resistance: mechanisms, epidemiology, and consequences for treatment. Am J Med. 2012;125(1 Suppl):S3-13.
43. Lass-Flörl C, Perkhofer S, et al. In vitro susceptibility testing in fungi: a global perspective on a variety of methods. Mycoses. 2010;53(1):1-11.
44. •• Eschenauer GA, Carver PL. The Evolving Role of Antifungal Susceptibility Testing. Pharmacotherapy. 2013 April 1. [Epub ahead of print]. This paper discusses the role of antifungal susceptibility testing, including clinical aspects.
45. Clinical and Laboratory Standards Institute. Method for Antifungal Disk Diffusion Susceptibility Testing of Yeasts. Approved guideline, 2nd ed. Wayne, PA: Clinical and Laboratory Standards Institute; 2009. CLSI publication M44-A2.
46. Clinical and Laboratory Standards Institute. Method for Antifungal Disk Diffusion Susceptibility Testing of Nondermatophyte Filamentous Fungi. Approved guideline. Wayne, PA: Clinical and Laboratory Standards Institute; 2010. CLSI publication M51-A.
47. Pfaller MA, Messer SA, et al. In vitro susceptibility testing of filamentous fungi: comparison of Etest and reference microdilution methods for determining itraconazole MICs. J Clin Microbiol. 2000;38(9):3359-61.
48. Pfaller MA, Boyken L, et al. Evaluation of the etest method using Mueller-Hinton agar with glucose and methylene blue for determining amphotericin B MICs for 4,936 clinical isolates of Candida species. J Clin Microbiol. 2004;42(11):4977-9.
49. Wiederhold NP. Paradoxical echinocandin activity: a limited in vitro phenomenon? Med Mycol. 2009;47 Suppl 1:S369-375.
50. Pfaller MA, Diekema DJ, et al. Multicenter comparison of the VITEK 2 antifungal susceptibility test with the CLSI broth microdilution reference method for testing amphotericin B, flucytosine, and voriconazole against Candida spp. J Clin Microbiol. 2007;45(11):3522-8.
51. Astvad KM, Perlin DS, et al. Evaluation of caspofungin susceptibility testing by the new Vitek 2 AST-YS06 yeast card using a unique collection of FKS wild-type and hot spot mutant isolates, including the five most common candida species. Antimicrob Agents Chemother. 2013;57(1):177-82.
52. Kappe R, Rimek D. Mycoserology - did we move on? Aspergillus. Mycoses. 2010;53 Suppl 1:26-9.
53. •• Peman J, Zaragoza R. Combined use of nonculture-based lab techniques in the diagnosis and management of critically ill patients with invasive fungal infections. Expert Rev Anti Infect Ther. 2012;10(11):1321-30. This paper discusses the impact of nonculture-based techniques and their clinical value.
54. Marchetti O, Lamoth F, et al. ECIL recommendations for the use of biological markers for the diagnosis of invasive fungal diseases in leukemic patients and hematopoietic SCT recipients. Bone Marrow Transplant. 2012;47(6):846-54.
55. Mikulska M, Calandra T, et al. The use of mannan antigen and anti-mannan antibodies in the diagnosis of invasive candidiasis: recommendations from the Third European Conference on Infections in Leukemia. Crit Care. 2010;14(6):R222.
56. Yeo SF, Wong B. Current status of nonculture methods for diagnosis of invasive fungal infections. Clin Microbiol Rev. 2002;15(3):465-84.
57. Wheat LJ, Walsh TJ. Diagnosis of invasive aspergillosis by galactomannan antigenemia detection using an enzyme immunoassay. Eur J Clin Microbiol Infect Dis. 2008;27(4):245-51.
58. Maertens J, Buve K, et al. Galactomannan serves as a surrogate endpoint for outcome of pulmonary invasive aspergillosis in neutropenic hematology patients. Cancer. 2009;115(2):355-62.
59. Clancy CJ, Jaber RA, et al. Bronchoalveolar lavage galactomannan in diagnosis of invasive pulmonary aspergillosis among solid-organ transplant recipients. J Clin Microbiol. 2007;45(6):1759-65.
60. •• Hage CA, Knox KS, et al. Antigen detection in bronchoalveolar lavage fluid for diagnosis of fungal pneumonia. Curr Opin Pulm Med. 2011;17(3):167-71. This review describes describes important findings when using bronchoalveolar lavage (BAL) for diagnosis of pulmonary mycoses.
61. Bretagne S, Marmorat-Khuong M, et al. Serum Aspergillus galactomannan antigen testing by sandwich ELISA: practical use in neutropenic patients. J Infect. 1997;35(1):7-15.
62. Maertens J, Verhaegen J, et al. Screening for circulating galactomannan as a noninvasive diagnostic tool for invasive aspergillosis in prolonged neutropenic patients and stem cell transplantation recipients: a prospective validation. Blood. 2001;97(6):1604-10.
63. Bellanger AP, Grenouillet F, et al. Retrospective assessment of beta-D-(1,3)-glucan for presumptive diagnosis of fungal infections. APMIS. 2011;119(4-5):280-6.
64. •• Karageorgopoulos DE, Vouloumanou EK, et al. beta-D-glucan assay for the diagnosis of invasive fungal infections: a meta-analysis. Clin Infect Dis. 2011;52(6):750-70. This paper presents a meta-analysis of relevant studies.
65. Thornton CR. Detection of invasive aspergillosis. Adv Appl Microbiol. 2010;70:187-216.
66. Chen SC. Kontoyiannis DP New molecular and surrogate biomarker-based tests in the diagnosis of bacterial and fungal infection in febrile neutropenic patients. Curr Opin Infect Dis. 2010;23(6):567-77.
67. •• Marcos JY, Pincus DH. Fungal diagnostics: review of commercially available methods. Methods Mol Biol. 2013;968:25-54. This paper gives an overview of commericially available methods for detection and identification of medically important fungi.
68. Balajee SA, Sigler L, et al. DNA and the classical way: identification of medically important molds in the 21st century. Med Mycol. 2007;45(6):475-90.
69. Kurzai O, Keith P, et al. Postmortem isolation of Pseudotaeniolina globosa from a patient with aortic aneurysm. Mycoses. 2003;46(3-4):141-4.
70. Schoch CL, Seifert KA, et al. Nuclear ribosomal internal transcribed spacer (ITS) region as a universal DNA barcode marker for fungi. Proc Natl Acad Sci USA. 2012;109(16):6241-6.
71. Nilsson RH, Kristiansson E, et al. Intraspecific ITS variability in the kingdom fungi as expressed in the international sequence databases and its implications for molecular species identification. Evol Bioinform Online. 2008;4:193-201.
72. Balajee SA, Borman AM, et al. Sequence-based identification of Aspergillus, fusarium, and mucorales species in the clinical mycology laboratory: where are we and where should we go from here? J Clin Microbiol. 2009;47(4):877-84.
73. Heinrichs G, de Hoog GS, et al. Barcode identifiers as a practical tool for reliable species assignment of medically important black yeast species. J Clin Microbiol. 2012;50(9):3023-30.
74. de Hoog GS, Haase G, et al. Taxonomy of medically important fungi in the molecular era. Lancet Infect Dis. 2013;13(5):385-6.
75. Parker C, Taylor D et al. NamesforLife Semantic Resolution Services for the Life Sciences. 2010. Available from Nature Precedings < http://dx.doi.org/10.1038/npre.2010.5137.1 >
76. Oliveira K, Haase G, et al. Differentiation of Candida albicans and Candida dubliniensis by fluorescent in situ hybridization with peptide nucleic acid probes. J Clin Microbiol. 2001;39(11):4138-41.
77. Shepard JR, Addison RM, et al. Multicenter evaluation of the Candida albicans/Candida glabrata peptide nucleic acid fluorescent in situ hybridization method for simultaneous dual-color identification of C. albicans and C. glabrata directly from blood culture bottles. J Clin Microbiol. 2008;46(1):50-5.
78. Hall L, Le Febre KM, et al. Evaluation of the Yeast Traffic Light PNA FISH probes for identification of Candida species from positive blood cultures. J Clin Microbiol. 2012;50(4):1446-8.
79. Heil EL, Daniels LM, et al. Impact of a rapid peptide nucleic acid fluorescence in situ hybridization assay on treatment of Candida infections. Am J Health Syst Pharm. 2012;69(21):1910-4.
80. Cuenca-Estrella M, Bassetti M, et al. Detection and investigation of invasive mould disease. J Antimicrob Chemother. 2011;66 suppl 1:i15-24.
81. Cuenca-Estrella M, Meije Y, et al. Value of serial quantification of fungal DNA by a real-time PCR-based technique for early diagnosis of invasive aspergillosis in patients with febrile neutropenia. J Clin Microbiol. 2009;47(2):379-84.
82. White PL, Bretagne S, Klingspor L, et al. Aspergillus PCR: one step closer to standardization. J Clin Microbiol. 2010;48(4):1231-40.
83. • Bille J. New nonculture-based methods for the diagnosis of invasive candidiasis. Curr Opin Crit Care. 2010;16(5):460-4. This article reviews important contributions in the nonconventional diagnostic approaches of invasive candidiasis.
84. •• White PL, Perry MD, et al. An update on the molecular diagnosis of invasive fungal disease. FEMS MicrobiolLett. 2009;296(1):1-10. This review provides the reader with access to assays with proficient clinical perfomance.
85. Uemura N, Makimura K, et al. Development of a loop-mediated isothermal amplification method for diagnosing Pneumocystis pneumonia. J Med Microbiol. 2008;57(Pt 1):50-7.
86. Najafzadeh MJ, Sun J, et al. Rapid identification of fungal pathogens by rolling circle amplification using Fonsecaea as a model. Mycoses. 2011;54(5):e577-582.
87. Dannaoui E, Schwarz P, et al. Molecular detection and identification of zygomycetes species from paraffin-embedded tissues in a murine model of disseminated zygomycosis: a collaborative European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Fungal Infection Study Group (EFISG) evaluation. J Clin Microbiol. 2010;48(6):2043-6.
88. Lau A, Chen S, et al. Development and clinical application of a panfungal PCR assay to detect and identify fungal DNA in tissue specimens. J Clin Microbiol. 2007;45(2):380-5.
89. Buitrago MJ, Aguado JM, et al. Efficacy of DNA amplification in tissue biopsy samples to improve the detection of invasive fungal disease. Clin Microbiol Infect. 2013;19(6):E271-277.
90. Rickerts V, Mousset S, et al. Comparison of histopathological analysis, culture, and polymerase chain reaction assays to detect invasive mold infections from biopsy specimens. Clin Infect Dis. 2007;44(8):1078-83.
91. Landlinger C, Preuner S, et al. Diagnosis of invasive fungal infections by a real-time panfungal PCR assay in immunocompromised pediatric patients. Leukemia. 2010;24(12):2032-8.
92. White PL, Perry MD, et al. Critical stages of extracting DNA from Aspergillus fumigatus in whole-blood specimens. J Clin Microbiol. 2010;48(10):3753-5.
93. White PL, Mengoli C, et al. Evaluation of Aspergillus PCR protocols for testing serum specimens. J Clin Microbiol. 2011;49(11):3842-8.
94. Loeffler J, Schmidt K, et al. Automated extraction of genomic DNA from medically important yeast species and filamentous fungi by using the MagNA Pure LC system. J Clin Microbiol. 2002;40(6):2240-3.
95. Loeffler J, Hebart H, et al. Contaminations occurring in fungal PCR assays. J Clin Microbiol. 1999;37:1200-2.
96. Westh H, Lisby G, et al. Multiplex real-time PCR and blood culture for identification of bloodstream pathogens in patients with suspected sepsis. Clin Microbiol Inf. 2009;15:544-51.
97. Steinmann J, Buer J, et al. Invasive aspergillosis in two liver transplant recipients: diagnosis by SeptiFast. Transpl Infect Dis. 2009;11:175-8.
98. Mancini N, Clerici D, et al. Molecular diagnosis of sepsis in neutropenic patients with haematological malignancies. J Med Microbiol. 2008;57:601-4.